ストックスクリーナーアプリを入手
1.13
0.44%
-0.005
プレマーケット:
1.13
Compass Therapeutics Inc (CMPX) 最新ニュース
Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares By Investing.com - Investing.com Nigeria
Compass Therapeutics (CMPX) Insider Buy: Chief Accounting Officer Neil Lerner Purchases 2,500 Shares - GuruFocus
Form 4 Compass Therapeutics, Inc. For: 25 September By Investing.com - Investing.com Nigeria
Is Compass Therapeutics, Inc. (CMPX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares - Investing.com
How Does FDA Feedback Change the Tovecimig Path for Compass Therapeutics (NASDAQ:CMPX)? - Kalkine Media
Compass Therapeutics (CMPX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Compass Therapeutics Is Maintained at Market Outperform by Citizens - Moomoo
Compass Therapeutics Shares Drop After Downgrade From Wedbush - marketscreener.com
Compass Therapeutics, Inc. (CMPX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX) - Seeking Alpha
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’ - Stocktwits
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Citizens maintains Market Outperform rating on Compass Therapeutics, $4 price target - TradingView
Guggenheim maintains Buy rating on Compass Therapeutics, $4 price target - TradingView
Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 - marketscreener.com
Wedbush downgrades Compass Therapeutics to Neutral, sets price target to $1 - TradingView
Cantor Fitzgerald reiterates Compass Therapeutics stock rating By Investing.com - Investing.com Canada
H.C. Wainwright cuts Compass Therapeutics stock price target on FDA trial recommendation - Investing.com Canada
Guggenheim cuts Compass Therapeutics stock price target on FDA trial requirement - Investing.com
HC Wainwright & Co. maintains Buy rating on Compass Therapeutics, $12 price target - TradingView
Citizens cuts Compass Therapeutics stock price target on FDA trial request - Investing.com Canada
COMPASS THERAPEUTICS INC. : WEDBUSH CUTS TO NEUTRAL FROM OUTPERFORM; CUTS TARGET PRICE TO $1 FROM $5 - Bitget
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside - Stocktwits
Compass Therapeutics Downgraded, Shares Plunge 32% After FDA Feedback - intellectia.ai
Wedbush downgrades Compass Therapeutics stock rating on FDA trial concerns - Investing.com Canada
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug - AOL.ca
Why Did Compass Therapeutics Stock Plunge Today?Compass Therapeutics (NASDAQ:CMPX) - benzinga.com
Compass shares fall after FDA tovecimig feedback - grafa.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback - Investing News Network
Compass Therapeutics stock price target maintained at $6 by Stifel - Investing.com Canada
Compass Therapeutics Faces FDA Pushback on Tovecimig Trial - TipRanks
Compass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares Fall - marketscreener.com
Form 8K Compass Therapeutics, Inc. For: 22 September By Investing.com - Investing.com Nigeria
CMPX Stock Slides As Traders Watch Volatile Support Zone - StocksToTrade
Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback - TradingView
Form 8K Compass Therapeutics, Inc. For: 22 September - Investing.com India
Compass says FDA seeks additional trial for lead asset (CMPX) - Seeking Alpha
Compass Therapeutics says FDA recommends survival trial before BLA for tovecimig in biliary tract cancer - TradingView
Compass Therapeutics, Inc. Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback - marketscreener.com
Compass Therapeutics’ CMPX Is Still Waiting On Its BLA Moment - Finimize
Compass Therapeutics Inc. (CMPX) Stock Price Target & Forecast - TradingKey
CCORF Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass (CMPX) Earnings Update: The EPS Result Is Below Expectation in the Current Update; After Earnings: Shares Finish 0.21% Higher on the DayProfit Cycle Analysis - vinanet.vn
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass (CMPX) Session: Finishes 4.23% Lower at $2.38; Technical Setup: the Supplied Trading Band Runs From $2.26 to $2.50 in the Current UpdateDollar Neutral Pair - vinanet.vn
NEXTBio Capital Management LP's Compass Therapeutics Inc(CMPX) Holding History - GuruFocus
Compass (CMPX) Earnings Data Review: The EPS Result Is Below Expectation in the Available Record; Investor Response: Shares Close 3.46% Higher in the Latest SessionCore Business Growth - vinanet.vn
Compass Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):